Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations
Recommended Citation
Young JL, Powell RN, Zabel C, Saal J, Welling LLM, Fortain J, and Ceresnie A. Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations. BMC Psychiatry 2023; 23(1):806.
Document Type
Article
Publication Date
11-6-2023
Publication Title
BMC psychiatry [electronic resource]
Abstract
OBJECTIVE: The aim was to develop and test a novel screen of adult ADHD, with a specific focus on clinical use. We designed a series of three studies to accomplish this aim.
METHOD: Study One (n = 155) and Study Two (n = 591) collected data via surveys to conduct exploratory and confirmatory factor analyses, respectively. Study Three analyzed the scale's psychometrics in a clinical sample (n = 151).
RESULTS: Study One and Study Two identified a 10-item scale with a two-factor structure. Study Three found good discriminant validity, sensitivity = 80.0%, specificity = 80.2%, and convergent validity with both the Brown Executive Function/Attention Scales, r (131) = .76, p < .001, and the Conner's Adult ADHD Rating Scales r (131) = .71, p < .001.
CONCLUSION: The scale demonstrated effectiveness in screening for ADHD in a psychiatric outpatient population. Its results may be used to identify patients that may benefit from thorough ADHD diagnostic procedures.
Medical Subject Headings
Adult; Humans; Attention Deficit Disorder with Hyperactivity; Psychiatric Status Rating Scales; Surveys and Questionnaires; Executive Function; Psychometrics; Reproducibility of Results
PubMed ID
37932675
Volume
23
Issue
1
First Page
806
Last Page
806
